Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. - Wikidata - awgldk - TriplyDB

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.

http://www.wikidata.org/entity/Q43883711

about

Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling Computational modeling of interactions between multiple myeloma and the bone microenvironment Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts Treatment of multiple myeloma bone disease: experimental and clinical data.Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.Osteoblastogenesis and tumor growth in myeloma.Advances in the understanding of myeloma bone disease and tumour growth.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma Bone disease in multiple myeloma: pathophysiology and management.Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts.Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL Lentivirus-mediated RNA interference of DC-STAMP expression inhibits the fusion and resorptive activity of human osteoclasts.Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells.Effect of zoledronate on oral wound healing in rats.The use of bisphosphonates in patients with breast cancer.Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype Monoclonal gammopathies of undetermined significance: a review.Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling.Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment.New insights into the pathophysiology and management of bone disease in multiple myeloma.Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis.Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma Multiple myeloma/hypercalcemia.Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.Myeloma as a model for the process of metastasis: implications for therapy Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth Bisphosphonates and bone metastases: current status and future directions.New therapeutic agents for the treatment of bone diseases.Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.CD44 deficiency inhibits unloading-induced cortical bone loss through downregulation of osteoclast activity.

P2860

Q27011865-5C119EE0-A47D-45FE-B636-4A6E7D4EDF42 Q28082335-CDD39FDD-8B58-45D2-924F-E68C3D08B04F Q28477867-CF38C5B2-C310-4BF7-83D1-C8E9DF8C3F15 Q28551480-707D352C-A9F0-4500-B64C-F58FA9A973FC Q30868833-CB2F10BE-59B6-4791-AC55-805DCBE66F25 Q33577408-A8B8E4F4-2EF2-4C77-B7C3-0AA28B0ABAFB Q33768466-4DF68DB4-63F5-4120-95E7-55AA31610C33 Q33829022-5B7DC04E-D59E-46CC-8E9D-3B8970712B30 Q33856318-0408E5B2-B3BB-47D4-B730-EAEDF00515D4 Q34045789-C497F62A-83E9-4D60-9713-3E220DF18C19 Q34242787-F95B5FAA-7CEE-4E7B-936B-66AFD05B3A38 Q34267974-FB78F11C-287F-4919-811C-B49D0FA6B4A6 Q34335082-A927E25E-4222-4738-AA60-B0ABDD3681E0 Q34404651-4AC2D16E-876C-4057-A062-2A390E445D52 Q34418934-AFA8C9A7-AA6A-438A-B6BE-BCD94774A293 Q34427554-4108AAA8-14E4-4E9A-BE7F-19AE9EBBCA1F Q34448984-AD57FD4B-37BB-4646-86E7-2E026CCA1461 Q34652128-6CABA5AC-A754-48BE-AEA1-66C9AA627586 Q34694368-E74A7F9C-567E-4AFD-ABAD-B511550F7F4E Q35039488-A25F0306-E750-48EB-B0FA-F53E83BCA201 Q35070415-6A3FA7E3-779E-468B-B37A-0710B40B95D6 Q35070420-C58FA827-5FBF-4EF8-9F2F-5DA888F5ED50 Q35170927-278A2F8A-8F4A-4E92-940D-9C9B70EEF9B7 Q35170930-300BC603-5D1F-45C1-8C36-C5688B4411EB Q35219019-3F5E581F-5F86-402A-A8EF-B2419CD9BA35 Q35220234-026FE57A-1E8A-4715-8D27-72ADD54FAE05 Q35591086-315AF025-46B5-40CF-9DDD-4EF138DDDF2B Q35642745-385C469D-24E3-4CF8-AB6E-EED08CF2B120 Q35700723-584FC129-5769-40AE-880A-DFC7FFC541EA Q35770718-73D0E8A7-9628-45A0-916B-67DF17FA448F Q35848298-800E7AF4-6484-4AEC-A8EE-0CC8F694BAEA Q35901084-D7CDA72A-3FD2-4413-A3AE-FDD94FEFCD55 Q35955440-31D202AC-F85D-4B87-A0FC-BF52D2069F87 Q36079800-662A214B-FC3B-42DC-BE95-517FDD9BEB8C Q36092153-63E1D397-1489-4B7C-B72D-46BD3FB9BEEC Q36118409-6ABBCD9C-C418-42BD-B1A7-CDADC2531A05 Q36161232-11C43D30-97AF-4BD9-BA52-FC6B267F1BBF Q36194583-3F365176-F1BB-4DCA-A314-CF5CA24BC949 Q36217148-21897D3D-4511-4C45-AFE4-476D6A31AC38 Q36245921-FAB80842-D0C6-4642-B98B-4201F4072DD8

P2860

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.

http://www.wikidata.org/entity/Q43883711

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Myeloma interacts with the bon ...... endent on osteoclast activity.

@en

Myeloma interacts with the bon ...... endent on osteoclast activity.

@nl

type

label

Myeloma interacts with the bon ...... endent on osteoclast activity.

@en

Myeloma interacts with the bon ...... endent on osteoclast activity.

@nl

prefLabel

Myeloma interacts with the bon ...... endent on osteoclast activity.

@en

Myeloma interacts with the bon ...... endent on osteoclast activity.

@nl

P1433

Q43883711-49BC2404-F7C3-4DE1-96DC-9BA4B950B87C

P1476

Q43883711-8CD9854D-9116-4821-8B1A-07FDD8D1A9AB

P2093

Q43883711-2617E1DF-B688-4218-A20A-5D522A10820B

Q43883711-9A1F42B0-6906-47A5-8CFA-2B8C94356447

Q43883711-F2FD89D3-AF59-437F-B5F6-A15673D3848F

Q43883711-FA26BF17-9D2F-4CB6-BB99-1DA237A72955

P2860

Q43883711-097A969F-84F4-4B9B-916A-A3B224ED3AD8

Q43883711-0C220DCB-2BA7-4B52-80E8-AF07365B8440

Q43883711-1D3CA911-0E9F-4B1B-9657-620341457B31

Q43883711-429A560D-AB88-4A6E-9F50-0E66EEFD8819

Q43883711-4C288897-BDD4-4C8D-B87F-7D9D616A3485

Q43883711-6B896749-1DEC-4015-B490-246274927FB5

Q43883711-6E4A624B-CB10-4655-8DEE-36A5F037D8B5

Q43883711-78BDBAD5-7106-4552-AE50-1A1A23D0FFC4

Q43883711-843C21C1-456C-467A-8661-BC1A92650DF0

Q43883711-92E2414D-4D8C-4C0F-B71F-A46F43C38272

P304

Q43883711-3400956A-8AE7-4C66-AD36-EEEB4B9B5E63

P31

Q43883711-AF25E7E1-BC36-4C9F-93C5-7F9CA6678D9B

P356

Q43883711-64AAC799-11E8-4173-BD3F-58351E4E7C2C

P407

Q43883711-3D0A7A33-8304-4B3A-BD38-BFDADF62C179

P433

Q43883711-E3267D1F-C969-426C-ACB9-3362871EA8BA

P478

Q43883711-68A946C1-7800-43E4-81F6-025CB657E927

P50

Q43883711-1B8A3919-4328-45AB-AA57-B7000A63800F

Q43883711-6174347A-5E05-4FE9-A806-09D223750C1D

P577

Q43883711-66FC8CDE-C249-44FD-9DD8-193F0E43995D

P5875

Q43883711-A03FD71E-300F-4979-8675-89357A36A631

P698

Q43883711-931D2D38-5D1D-4A4D-86D4-8F56D0BA403D

P921

Q43883711-6CC5C8C6-9812-4528-8DBE-97123B869E22

P356

J.1365-2141.2002.03257.X

P1433

British Journal of Haematology

P1476

Myeloma interacts with the bon ...... endent on osteoclast activity.

@en

P2093

Cherie L Johnson

http://www.w3.org/2001/XMLSchema#string

Joshua Epstein

http://www.w3.org/2001/XMLSchema#string

Roger N Pearse

http://www.w3.org/2001/XMLSchema#string

Yongwon Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.

TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma.

Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells.

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.

P304

278-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2141.2002.03257.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11520457

http://www.w3.org/2001/XMLSchema#string

P698

11841428

http://www.w3.org/2001/XMLSchema#string

P921